TMO

In the past six months (April to October 2026), Thermo Fisher Scientific's stock experienced several notable events, including stronger-than-expected first-quarter 2026 results with revenue of $11.01 billion and adjusted EPS of $5.44, and robust second-quarter 2026 results showing a 10.5% year-over-year revenue increase to $11.99 billion and a 13% rise in adjusted EPS to $6.03. Following these strong performances, management raised its full-year 2026 outlook. Key corporate activities included the completion of the acquisition of Clario for approximately $9 billion, expected to be immediately accretive to adjusted EPS, and the agreement to sell its microbiology business to Astorg for approximately $1.08 billion. The stock has shown a steady upward trend, trading near $651.45 in September, up roughly 6% over the trailing 30 days, and a 21.53% increase over the last 12 months, with generally positive analyst sentiment.